Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $8.3 million.

  • Lifecore Biomedical, Inc. \De\'s Cash & Equivalents fell 232.81% to $8.3 million in Q2 2025 from the same period last year, while for May 2025 it was $8.3 million, marking a year-over-year decrease of 232.81%. This contributed to the annual value of $8.3 million for FY2025, which is 232.81% down from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Cash & Equivalents stood at $8.3 million for Q2 2025, which was down 232.81% from $5.4 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year Cash & Equivalents high stood at $19.1 million for Q2 2023, and its period low was $609000.0 during Q4 2021.
  • Its 5-year average for Cash & Equivalents is $4.9 million, with a median of $2.7 million in 2022.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Cash & Equivalents tumbled by 7540.39% in 2021 and then soared by 182643.79% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Cash & Equivalents (Quarter) stood at $609000.0 in 2021, then skyrocketed by 875.04% to $5.9 million in 2022, then skyrocketed by 221.51% to $19.1 million in 2023, then plummeted by 50.47% to $9.5 million in 2024, then decreased by 12.59% to $8.3 million in 2025.
  • Its Cash & Equivalents was $8.3 million in Q2 2025, compared to $5.4 million in Q1 2025 and $9.5 million in Q4 2024.